Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Submit Guest Post

MHRA programme to address gaps in women’s health research

The Women’s Health Programme aims to improve evidence on how medicines and medical devices affect women, following finding that pregnant and breastfeeding women remain underrepresented in clinical trials.

Women's health

Women remain underrepresented in clinical research

iStock

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a new Women’s Health Programme to address longstanding evidence gaps in research and improve the safety and effectiveness of medicines and medical devices used by women.

Despite representing 51% of the population, women remain underrepresented in clinical research, limiting the evidence available on treatments during pregnancy, breastfeeding and across reproductive health.


An MHRA analysis of 4,614 UK clinical trial applications submitted between 2019 and 2023 found that pregnant women were represented in just 1.1% of trials, while breastfeeding women accounted for only 0.6%.

The programme aims to strengthen research, improve understanding of how biological factors and pregnancy influence responses to medicines, and support innovation in women’s health.

Women’s Health Minister Baroness Gillian Merron said: “For too long, women’s health has been overlooked. Women make up more than half our population, yet they have been underrepresented in the research that shapes the medicines and devices they rely on. That is not good enough, and we are determined to change it”.

“This new programme is a welcome step. Together with our renewed Women’s Health Strategy, it will mean better evidence, better treatments, and a health system that listens to women and works for them”, Merron added.

MHRA chief executive Lawrence Tallon commented: “Closing the gaps in our understanding of how the risks and benefits of medicines and medical devices differ for women is both a challenge and a huge opportunity”.

Women’s health is a major field for innovation. The UK’s FemTech sector already generates nearly £300 million in annual turnover, with technologies being developed across reproductive health, long-term conditions and healthy ageing, Tallon added.

Health Research Authority deputy director of policy and partnerships Naho Yamazaki welcomed the new approach.

“We welcome the MHRA’s Women’s Health Programme and its ambition to strengthen the evidence base for women’s health. Ensuring that people who are underrepresented in research are considered and included in clinical trials is essential if research is to generate evidence that is relevant to the populations who will ultimately use new medicines and treatments”.

Michele Riddalls OBE, CEO of PAGB, The Consumer Healthcare Association, also supported the initiative, highlighting the importance of responsible innovation and improved access to treatments.

She said: “In recent times we have seen both low-dose Estradiol vaginal products and Estriol cream reclassified which have transformed access to Hormone Replacement Therapy (HRT) for thousands of women, positive examples of providing women with greater choice and more convenient access to treatments”.

The programme forms part of the MHRA's 2030 Strategy and the government’s renewed Women’s Health Strategy and corresponding work in Wales, Northern Ireland and Scotland.

The announcement is to be made in London this week at the inaugural DIA-MHRA Global Summit, as part of London Life Sciences Week.